Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 391

1.

Hospital and procedure incidence of pediatric retained surgical items.

Wang B, Tashiro J, Perez EA, Lasko DS, Sola JE.

J Surg Res. 2015 Mar 24. pii: S0022-4804(15)00317-0. doi: 10.1016/j.jss.2015.03.054. [Epub ahead of print]

PMID:
25908101
2.

Resource utilization patterns of pediatric esophageal foreign bodies.

Teisch LF, Tashiro J, Perez EA, Mendoza F, Sola JE.

J Surg Res. 2015 Mar 24. pii: S0022-4804(15)00318-2. doi: 10.1016/j.jss.2015.03.055. [Epub ahead of print]

PMID:
25899146
3.

Hospital survival of aortic dissection in children.

Hua HU, Tashiro J, Allen CJ, Rey J, Perez EA, Sola JE.

J Surg Res. 2015 Mar 18. pii: S0022-4804(15)00298-X. doi: 10.1016/j.jss.2015.03.030. [Epub ahead of print]

PMID:
25881788
4.

Effective Targeting of Estrogen Receptor Negative Breast Cancers with the Protein Kinase D inhibitor CRT0066101.

Borges S, Perez EA, Thompson EA, Radisky DC, Geiger XJ, Storz P.

Mol Cancer Ther. 2015 Apr 7. pii: molcanther.0945.2014. [Epub ahead of print]

PMID:
25852060
5.

Prognostic associations of 25 hydroxy vitamin D in NCIC CTG MA.21, a phase III adjuvant randomized clinical trial of three chemotherapy regimens in high-risk breast cancer.

Lohmann AE, Chapman JA, Burnell MJ, Levine MN, Tsvetkova E, Pritchard KI, Gelmon KA, O'Brien P, Han L, Rugo HS, Albain KS, Perez EA, Vandenberg TA, Chalchal HI, Sawhney RP, Shepherd LE, Goodwin PJ.

Breast Cancer Res Treat. 2015 Apr;150(3):605-11. doi: 10.1007/s10549-015-3355-x. Epub 2015 Apr 2.

PMID:
25833209
7.

Folate Receptor-α (FOLR1) Expression and Function in Triple Negative Tumors.

Necela BM, Crozier JA, Andorfer CA, Lewis-Tuffin L, Kachergus JM, Geiger XJ, Kalari KR, Serie DJ, Sun Z, Aspita AM, O'Shannessy DJ, Maltzman JD, McCullough AE, Pockaj BA, Cunliffe HE, Ballman KV, Thompson EA, Perez EA.

PLoS One. 2015 Mar 27;10(3):e0122209. doi: 10.1371/journal.pone.0122209. eCollection 2015.

8.

Post-ECMO chest tube placement: A propensity score-matched survival analysis.

Tashiro J, Perez EA, Lasko DS, Sola JE.

J Pediatr Surg. 2015 Feb 19. pii: S0022-3468(15)00118-9. doi: 10.1016/j.jpedsurg.2015.02.038. [Epub ahead of print]

PMID:
25783367
9.

Determinants of survival and resource utilization for pediatric extracorporeal membrane oxygenation in the United States 1997-2009.

Bokman CL, Tashiro J, Perez EA, Lasko DS, Sola JE.

J Pediatr Surg. 2015 Feb 19. pii: S0022-3468(15)00122-0. doi: 10.1016/j.jpedsurg.2015.02.042. [Epub ahead of print]

PMID:
25783363
10.

Reply to e.a. Rakha et Al.

Wolff AC, Hammond ME, Hicks DG, Allison KH, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Dowsett M, McShane LM, Hayes DF.

J Clin Oncol. 2015 Apr 10;33(11):1302-4. doi: 10.1200/JCO.2014.59.7559. Epub 2015 Mar 9. No abstract available.

PMID:
25753441
11.

Endpoint comparison for bone mineral density measurements in North Central Cancer Treatment Group cancer clinical trials N02C1 and N03CC (Alliance).

Dueck AC, Singh J, Atherton P, Liu H, Novotny P, Hines S, Loprinzi CL, Perez EA, Tan A, Burger K, Zhao X, Diekmann B, Sloan JA; for the Alliance for Clinical Trials in Oncology.

Osteoporos Int. 2015 Mar 7. [Epub ahead of print]

PMID:
25749740
12.

Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane.

Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Velikova G, Olivo MS, He Y, Dutcus CE, Cortes J.

J Clin Oncol. 2015 Feb 20;33(6):594-601. doi: 10.1200/JCO.2013.52.4892. Epub 2015 Jan 20.

PMID:
25605862
13.

Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the north central cancer treatment group n9831 adjuvant trastuzumab trial.

Perez EA, Thompson EA, Ballman KV, Anderson SK, Asmann YW, Kalari KR, Eckel-Passow JE, Dueck AC, Tenner KS, Jen J, Fan JB, Geiger XJ, McCullough AE, Chen B, Jenkins RB, Sledge GW, Winer EP, Gralow JR, Reinholz MM.

J Clin Oncol. 2015 Mar 1;33(7):701-8. doi: 10.1200/JCO.2014.57.6298. Epub 2015 Jan 20.

PMID:
25605861
14.

HER2 testing and its predictive utility in anti-HER2 breast cancer therapy.

Advani PP, Crozier JA, Perez EA.

Biomark Med. 2015;9(1):35-49. doi: 10.2217/bmm.14.95.

PMID:
25605454
15.

Pediatric emergency department thoracotomy: a large case series and systematic review.

Allen CJ, Valle EJ, Thorson CM, Hogan AR, Perez EA, Namias N, Zakrison TL, Neville HL, Sola JE.

J Pediatr Surg. 2015 Jan;50(1):177-81. doi: 10.1016/j.jpedsurg.2014.10.042. Epub 2014 Oct 26.

PMID:
25598119
16.

Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial.

Liu S, Chapman JA, Burnell MJ, Levine MN, Pritchard KI, Whelan TJ, Rugo HS, Albain KS, Perez EA, Virk S, Barry G, Gao D, O'Brien P, Shepherd LE, Nielsen TO, Gelmon KA.

Breast Cancer Res Treat. 2015 Jan;149(2):439-48. doi: 10.1007/s10549-014-3259-1. Epub 2015 Jan 1.

PMID:
25552364
17.

Yeast HXK2 gene reverts glucose regulation mutation of penicillin biosynthesis in P. chrysogenum.

Pérez EA, Fernández FJ, Fierro F, Mejía A, Marcos AT, Martín JF, Barrios-González J.

Braz J Microbiol. 2014 Oct 9;45(3):873-83. eCollection 2014.

18.

Perspectives from the American Society of Clinical Oncology 2014 Conference: breast cancer highlights.

Crozier JA, Perez EA.

Future Oncol. 2014 Oct;10(12):1897-9. doi: 10.2217/fon.14.151. No abstract available.

19.

Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.

Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE Jr, Martino S, Rastogi P, Gralow J, Swain SM, Winer EP, Colon-Otero G, Davidson NE, Mamounas E, Zujewski JA, Wolmark N.

J Clin Oncol. 2014 Nov 20;32(33):3744-52. doi: 10.1200/JCO.2014.55.5730. Epub 2014 Oct 20.

PMID:
25332249
20.

Highlights in breast cancer from the 2014 American Society of Clinical Oncology® annual meeting.

Perez EA.

Clin Adv Hematol Oncol. 2014 Jul;12(7):451-3. No abstract available.

PMID:
25322325
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk